STAT

•

チャンネル • 2個の番組

ビジネス

ビジネス

アップデート：毎週
ニュース

ニュース

アップデート：隔週

5月21日

402: Guarding biotech from China and big bets in longevity

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar's comments that the company is publishing “not the right structures” in their research publications. Listeners also will hear Allison's interview with Joe Betts-LaCroix, CEO of the Sam Altman-backed longevity company Retro Biosciences. Retro is preparing for its first clinical data readout and examining just how much impact AI can have in drug development. The hosts also discuss colleague Damian Garde's article on how China is tearing biotech apart and one self-appointed spokesperson’s strategy.

5月21日

•

44分
5月14日

401: Makary’s departure and Cassidy’s tenuous Senate seat

This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle Diamantas. Washington correspondent Chelsea Cirruzzo also joins us to discuss a closely tracked Republican Senate primary election this weekend. Bill Cassidy, chair of the Senate health committee, is up against two upstart rivals, including a Trump-backed candidate. The outcome of the primary could have far reaching implications for Trump’s health care agenda.

5月14日

•

41分
2018/05/24

Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen

How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.

2018/05/24

•

28分
5月7日

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win for Cytokinetics, and FDA Commissioner Marty Makary’s White House troubles. Oh, by the way, this is the 400th episode of your favorite biotech podcast.

5月7日

•

33分
2018/03/15

Episode #2 - Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies

Did Elizabeth Holmes get off easy? Why does biotech bother with SXSW? And what does shoving a tube into a dead cow’s throat have to do with biotech?

2018/03/15

•

22分
4月9日

396: A new trick for old science, and biotech VCs' scrambled playbook

Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.

4月9日

•

32分
2018/03/29

Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card

Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?

2018/03/29

•

24分
4月2日

395: Biotech investors' plea to Trump, and a busy M&A week

How has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison go on her vacation? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's weekly biotech podcast. Biotech investor Rod Wong joins us to talk about why an industry-patient coalition he's part of sent a letter to President Trump asking for more regulatory flexibility at the FDA. We also discuss the U.S. approval of Eli Lilly's obesity pill, recent deal-making by large pharma companies, a strange story about promotion of psychedelic drugs on YouTube, and more.

4月2日

•

32分
2018/03/08

Episode #1 - Shkreli's sentence, biotech froth, and a blood party

How long is Martin Shkreli going to be in prison? Is the biotech bubble about to burst? And what's it like to attend a blood-swapping gala? Listen to our first episode of, "The Readout LOUD."

2018/03/08

•

18分
2022/10/06

229: Nobels for science, biotech dealmaking, & a friendly FTC

The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winning work in medicine and chemistry. We also discuss the latest news in the life sciences, including the state of biotech dealmaking and the evolution of Amylyx Pharmaceuticals.

2022/10/06

•

28分

Voices from the frontiers of health and medicine